| Ident. | Authors (with country if any) | Title |
|---|
| 000157 (2016) |
James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; Gabriela Reyes [Canada] ; Vanessa Omana [Canada] ; Jonathan M. Brotchie [Canada] | Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque |
| 000552 (2015) |
Yilong Ma [États-Unis] ; Tom H. Johnston [Canada] ; Shichun Peng [États-Unis] ; Chuantao Zuo [République populaire de Chine] ; James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Yihui Guan [République populaire de Chine] ; David Eidelberg [États-Unis] ; Jonathan M. Brotchie [Canada] | Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. |
| 000879 (2014) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada] | UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. |
| 000C48 (2013) |
Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Susan H. Fox ; Jonathan M. Brotchie | The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. |
| 000F21 (2013) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque |
| 000F48 (2013) |
Karen L. Eskow Jaunarajs [États-Unis] ; David G. Standaert [États-Unis] ; Tacey X. Viegas [États-Unis] ; Michael D. Bentley [États-Unis] ; Zhihao Fang [États-Unis] ; Bekir Dizman [États-Unis] ; Kunsang Yoon [États-Unis] ; Rebecca Weimer [États-Unis] ; Paula Ravenscroft [Canada] ; Tom H. Johnston [Canada] ; Michael P. Hill [Canada] ; Jonathan M. Brotchie [Canada] ; Randall W. Moreadith [États-Unis] | Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit |
| 001047 (2013) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque |
| 001136 (2012) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Michael N. Gandy [Australie] ; M. Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada] | The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset |
| 001215 (2012) |
Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Ahmed Aman ; Susan H. Fox ; Jonathan M. Brotchie | L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. |
| 001325 (2012) |
Tom H. Johnston [Canada] ; Zak Millar ; Philippe Huot ; Keith Wagg ; Sherri Thiele ; Danielle Salomonczyk ; Christopher J. Yong-Kee ; Michael N. Gandy ; Matthew Mcildowie ; Katie D. Lewis ; Jordi Gomez-Ramirez ; Joohyung Lee ; Susan H. Fox ; Mathew Martin-Iverson ; Joanne E. Nash ; Matthew J. Piggott ; Jonathan M. Brotchie | A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. |
| 001445 (2012) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease |
| 001509 (2012) |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Qin Li [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A critique of available scales and presentation of the non‐human primate dyskinesia rating scale |
| 001563 (2012) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased Levels of 5-HT1A Receptor Binding in Ventral Visual Pathways in Parkinson's Disease |
| 001616 (2012) |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale |
| 001676 (2011) |
James B. Koprich ; Tom H. Johnston ; Philippe Huot ; M. Gabriela Reyes ; Maria Espinosa ; Jonathan M. Brotchie | Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein |
| 001854 (2011) |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
| 001991 (2011) |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's Disease |
| 001B02 (2010) |
Tom H. Johnston [Canada] ; Susan H. Fox ; Matthew J. Mcildowie ; Matthew J. Piggott ; Jonathan M. Brotchie | Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. |
| 001B55 (2010) |
James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; M Gabriela Reyes [Canada] ; Xuan Sun [Canada] ; Jonathan M. Brotchie [Canada] | Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease |
| 001C64 (2010) |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |
| 001D23 (2010) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations |
